BB
TBRA

BB Biotech’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

BB Biotech’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-468,000
Closed -$5.88M – 30
2016
Q2 		$5.88M Buy
+468,000
New +$4.36M 0.23% 30

Other funds holding TBRA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BB Biotech's TBRA Position: Q3 2016 in Review

BB Biotech sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q3 2016, closing a stake of 468,000 shares — an estimated $5.88M sold.

BB Biotech first reported a position in TBRA in Q2 2016 and held it in 1 quarter. The position peaked at $5.88M in Q2 2016. 68 funds tracked by Wall St. Rank hold TBRA as of Q3 2016.

  • BB Biotech reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • BB Biotech sold 468,000 Tobira Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $5.88M.
  • BB Biotech first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2016 and held it in 1 quarter.
  • BB Biotech's Tobira Therapeutics, Inc. Common Stock position peaked at $5.88M in Q2 2016.
  • 68 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q3 2016.

Based on BB Biotech's 13F filing for Q3 2016, filed 10 Nov 2016.